Review

Clin Ter 2025; 176 (4):495-497 doi: 10.7417/CT.2025.5253

Innovative Strategies for Hip Synovial Chondromatosis and Its Medico-Legal Implications

G. Basile[1], L. Bianco Prevot[2], V. Bolcato[3], M. Basile[4], L.P. Tronconi[5,6]

[1]Department of Biomedical Sciences and Public Health, Marche Polytechnic University UOR Forensic Medicine, Ancona, Italy; [2]IRCCS Orthopedic Institute Galeazzi, Milan, Italy; [3]Astolfi Associati Law Firm, Milan, Italy; [4] Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, Italy; [5]Department of Human and Life Sciences, European University of Rome, Rome, Italy; [6]Maria Cecilia Hospital, Cotignola (RA), Italy

Abstract

Primary synovial chondromatosis of the hip is a rare pathology characterized by metaplastic changes in the synovium, leading to the formation of cartilage nodules and, eventually, free intra-articular bodies. Early manifestations, such as pain, stiffness, and limited mobility, require timely differential diagnostic process through imaging techniques, with magnetic resonance imaging being the gold standard diagnostic method, complemented by histopathological analysis. Considering the rarity of the condition, the diagnostic suspicion is linked to the expertise of the professional and the referral to specialized centers/professionals. While, the evolution toward minimally invasive surgical techniques and a multidisciplinary approach has improved clinical outcomes, the level of evidence in the different surgical approach are worthy of further long-term investigation. Furthermore, the definition of multidisciplinary diagnostic-therapeutic protocols based on evidence is of importance. In conclusion, the careful management of the condition, along with detailed docu mentation, is essential to minimize medico-legal implications associated with potential diagnostic delays, interpretative errors or improper surgical approach indication. ***Clin Ter 2025; 176 (4):495-497 doi: 10.7417/CT.2025.5253***

Keywords: *Hip joint, Synovial chondromatosis, Medico-legal implications*

Primary synovial chondromatosis of the hip is an infrequently observed pathology that, despite its rarity, presents a significant diagnostic and therapeutic challenge. It is a condition characterized by metaplastic alteration of the synovium, leading to the formation of ectopic cartilage nodules which, in the progressive phase, may result in the generation of free bodies within the joint cavity (1). This phenomenon, whose underlying mechanisms are still not fully understood, is gaining increasing attention in musculoskeletal research due to the risk that delayed diagnosis may lead to progressive joint damage, with serious functional and psychosocial consequences. (2). Clinically, the evolution of primary synovial chondromatosis of the hip initially presents with nonspecific symptoms which often lead the clinician to suspect other degenerative or inflammatory conditions. In this regard, imaging techniques are indispensable tools for early diagnosis. Magnetic resonance imaging, due to its high sensitivity in detecting synovial structural changes and distinguishing between fibrocartilaginous components and free bodies, stands out as the diagnostic method of choice, while three-dimensional computed tomography provides additional anatomical details to aid therapeutic planning. Radiographs, sufficient to identify atypical calcifications and secondary bone changes, and ultrasonography, although limited in detail, remain valuable screening tools, especially in the early stages of the disease (3). Beyond diagnostic aspects, it is necessary to highlight the importance of histopathological analysis to confirm the diagnosis and differentiate primary synovial chondromatosis from other pathologies with overlapping clinical manifestations, such as pigmented villonodular synovitis or other forms of inflammatory arthropathy. Histological characterization reveals abnormal proliferation of synovial cells accompanied by the formation of cartilage nodules, which in advanced stages may ossify. In this context, timely diagnosis not only enables early intervention, preventing the progressive deterioration of joint function but also allows for a targeted therapeutic approach, ranging from pharmacological management of symptoms to surgical intervention, which in recent years has seen significant development toward minimally invasive techniques. The evolution of joint surgery, with the introduction of endoscopic techniques and intraoperative navigation, has revolutionized the treatment of primary synovial chondromatosis of the hip, allowing for the minimization of surgical impact and acceleration of functional recovery (4). The traditional surgical approach, based on synovectomy and excision of free bodies, has progressively integrated with methods that reduce surgical trauma, ensuring the patient a less painful postoperative course and better preservation of joint function. However, to date there is a lack of evidence supporting the arthroscopic approach over open arthrotomy, evaluating functional outcomes and recurrence (5).

Correspondence: Luca Bianco Prevot, IRCCS Orthopedic Institute Galeazzi, Milan, Italy - E-mail: luca.bianco96@gmail.com

ISSN 1972-6007

In addition to strictly clinical-diagnostic aspects, another area that deserves attention concerns the medico-legal implications associated with the management of primary synovial chondromatosis of the hip and the potential professional repercussion as malpractice. Diagnostic delay could be the first argument for litigation, as it could determine not only a worsening of the disease progression but also higher patient disability or reduced option of favorable outcome or higher recurrence rate. The complexity of the clinical picture, combined with the variability of symptomatic presentations, makes an accurate and timely evaluation by the physician difficult but crucial, as they are required to operate in a context of high diagnostic difficulty. In addition to delays in diagnosis and treatment, there may also be disputes about treatment options or post-operative complications of a neurological, functional or osteo-metabolic nature. This is all the more true if there is an incorrect indication for the type of surgery, or if the surgery is clearly wrongly performed, or if the patient is not given clear information about the options. In this regard, it is essential that each phase of the diagnostic process is thoroughly documented, highlighting the reasons behind the clinical decisions made . In particular, the need for further high-level instrumental examinations or the indication to look for a reference center for the treatment of this rare pathology must be clearly disclosed to the patient. Considering also the surgical option, proper patient information, through a detailed informed consent process, is pivotal in discussing the limitations in diagnosing rare and difficult pathologies and the potential for clinical progression despite the adoption of the best therapeutic strategies (6). The increasing focus on the physician-patient relationship, based on transparency and mutual trust, represents a key element not only for the successful clinical outcome but also for reducing the risk of medico-legal complaints, often related to the perception of an inadequate case management. It is also important to reflect on the role of guidelines and standardized operational protocols, which are essential tools to guide the diagnostic and therapeutic path in the presence of rare diseases such as primary synovial chondromatosis of the hip and identify reference centers or professionals. These statute, developed by multidisciplinary groups and updated based on the latest scientific evidence, reduce the uncertainty in a complex diagnostic process, help professionals with approach evidence and secure the patient with the best evidence. In a context where technological innovation and surgical methods are progressing rapidly, the establishment of shared protocols and their rigorous application constitutes a guarantee of quality, both from a clinical and medico-legal perspective. The concept of 'special technical difficulty' should also be taken into account. In legal terms, it denotes a particularly complex clinical scenario arising from factors such as the rarity of the condition, diagnostic challenges, the disease's natural course, or the complexity of available treatments—as is the case here.Thus, in the event of litigation, it is expected that the average practitioner will be more excused than in the case of a prolonged or less favorable diagnosis with harmful consequences, precisely because of a greater difficulty than in a normal routine. The development of diagnostic-therapeutic algorithms that combine clinical evaluation with instrumental findings allows for a more comprehensive understanding of the condition, thus supporting timely and personalized treatment strategies. Moreover, collaboration among specialists from various disciplines – radiologists, orthopedic surgeons, rheumatologists, and pathologists – is essential for ensuring integrated and multidimensional management of the disease, starting with the definition of treatment protocols (7). Here, as in general for rare diseases, the role of experts, pathology networks and scientific societies in defining consensus, is fundamental. This approach fosters a virtuous cycle where ongoing interdisciplinary collaboration improves both diagnosis and treatment, while also helping to prevent potential medico-legal complications. In light of the above, it is evident that primary synovial chondromatosis of the hip, while representing a low-incidence pathology, requires particular attention from multiple perspectives. The evolution of surgical techniques, along with the establishment of standardized operational protocols, has also provided new therapeutic perspectives capable of integrating and, in some cases, replacing traditional intervention methods, minimizing the risk of recurrences and complications. It is therefore desirable that the scientific community focus on prospective studies and targeted clinical trials, capable of providing further evidence on improving therapeutic outcomes and defining preventive strategies that could also limit potential medico-legal implications.

Conclusion

The management of primary synovial chondromatosis of the hip represents a test case for the synergy between clinical innovation, diagnostic rigor, clinical evidence definition and medico-legal reasoning. These elements, when expertly integrated, can lead to a significant evolution of the therapeutic paradigm, an improvement of the patients' quality of life and a serene healthcare professionals work.

Conflict of interest

The author declares that he has no conflict of interest regarding this manuscript.

References

1. Mora R, Soldini A, Raschellà F, et al. Primitive synovial chondromatosis of the hip joint. Ital J Orthop Traumatol 1992; 18:231–239.
2. Knoeller SM. Synovial osteochondromatosis of the hip joint. Etiology, diagnostic investigation and therapy. Acta Orthop Belg 2001; 67:201–210.
3. Mak MS, Teh J. Magnetic resonance imaging of the hip: anatomy and pathology. Pol J Radiol 2020; 85:e489.
4. Zhu Y, Zhang X, Wang J, et al. Revision hip arthroscopy for hip synovial chondromatosis is effective despite inferior postoperative clinical outcomes compared to patients undergoing primary hip arthroscopy: a matched control study with minimum 2-year follow-up. J Orthop Surg Res 2024; 19:1–11.
5. Soul Kim H, Ok CH, Chang JS, et al. Outcomes of Open Arthrotomy and Arthroscopic Surgery for Primary Synovial Chondromatosis of the Hip: A Comparative Study With Propensity Score Matching. Am J Sports Med; 53. Epub ahead of print 2025. DOI: 10.1177/03635465251316312.

6. Basile G. Enabling true decision making through personalized informed consent: omne ignotum pro terribili. Chirurgia (Bucur); 37. Epub ahead of print May 2024. DOI: 10.23736/S0394-9508.23.05665-6.
7. Basile G, Prevot LB, Tronconi LP, et al. Synchronous Primary Synovial Chondromatosis of the Hip: An Integrated Perspective on Physiotherapeutic Support. Clin Ter 2024; 175: 216–218.